Document Detail


New therapeutic options for onychomycosis.
MedLine Citation:
PMID:  22533461     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
INTRODUCTION: Onychomycosis is a fungal infection of the nail apparatus that affects 10 - 30% of the global population. Current therapeutic options for onychomycosis have a low to moderate efficacy and result in a 20 - 25% rate of relapse and reinfection. New therapeutic options are needed to broaden the spectrum of treatment options and improve the efficacy of treatment.
AREAS COVERED: This review discusses the emerging pharmacotherapeutics; including topical reformulations of terbinafine, new azole molecules for systemic and topical administration, topical benzoxaboroles and topical polymer barriers. The paper also discusses device-based options, which may be designed to activate a drug or to improve drug delivery, such as photodynamic therapy and iontophoresis; laser device systems have also begun to receive regulatory approval for onychomycosis.
EXPERT OPINION: Device-based therapeutic options for onychomycosis are expanding more rapidly than pharmacotherapy. Systemic azoles are the only class of pharmacotherapy that has shown a comparable efficacy to systemic terbinafine; however terbinafine remains the gold standard. The most notable new topical drugs are tavaborole, efinaconazole and luliconazole, which belong to the benzoxaborole and azole classes of drugs. Photodynamic therapy, iontophoresis and laser therapy have shown positive initial results, but randomized controlled trials are necessary to determine the long-term success of these devices.
Authors:
Aditya K Gupta; Fiona C Simpson
Publication Detail:
Type:  Journal Article; Review     Date:  2012-04-25
Journal Detail:
Title:  Expert opinion on pharmacotherapy     Volume:  13     ISSN:  1744-7666     ISO Abbreviation:  Expert Opin Pharmacother     Publication Date:  2012 Jun 
Date Detail:
Created Date:  2012-05-18     Completed Date:  2012-09-11     Revised Date:  2013-11-06    
Medline Journal Info:
Nlm Unique ID:  100897346     Medline TA:  Expert Opin Pharmacother     Country:  England    
Other Details:
Languages:  eng     Pagination:  1131-42     Citation Subset:  IM    
Affiliation:
Division of Dermatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada. agupta@execulink.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Allylamine / administration & dosage
Antifungal Agents / administration & dosage*
Azoles / administration & dosage
Bicyclo Compounds, Heterocyclic / administration & dosage
Boron Compounds / administration & dosage
Echinocandins / administration & dosage
Humans
Iontophoresis
Lasers
Naphthalenes / administration & dosage
Onychomycosis / drug therapy*
Photochemotherapy
Polymers / administration & dosage
Chemical
Reg. No./Substance:
0/Antifungal Agents; 0/Azoles; 0/Bicyclo Compounds, Heterocyclic; 0/Boron Compounds; 0/Echinocandins; 0/Naphthalenes; 0/Polymers; 107-11-9/Allylamine; 91161-71-6/terbinafine
Comments/Corrections
Erratum In:
Expert Opin Pharmacother. 2013 Jan;14(1):149

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The Water Tetramer, Pentamer, and Hexamer in Inert Matrices.
Next Document:  Juvenile and adult-onset ALS/MND among Africans: incidence, phenotype, survival: a review.